TELA Bio, Inc.

NASDAQ:TELA

Medical - Devices

Healthcare
$1.14 +8.26%

+$0.09 today

Market cap
$51.00M
Beta
1.36
P/E (TTM)
-1.5
EPS (TTM)
-$0.72
52W Low $0.50High $1.69

Volume 0.22M

Average 0.17M

TELA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

TELA Bio, Inc.NASDAQ: TELA

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $613K fell 37.8% year over year, behind the -23.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 24.9% from the prior quarter. Over 3 fiscal years it compounded at -1.6% a year.

Context

  • Stock-based compensation amounted to 4.7% of revenue in FY2025, down 1.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -37.8% toward the trailing-twelve-month pace of -23.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$613K-24.9% QoQ
Last fiscal yearDec 2025
$3.8M-13.0% YoY
LTMJun 2026
$3.2M-23.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.8%——
1 year-13.0%——
3-year CAGR-1.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.8M USD
Year-over-year change
-13.0%
4-year CAGR
+0.9%

Stock-Based Compensation vs competitors

How TELA compares with its peers on the latest reported figures

  • TELA's LTM Jun 2026 stock-based compensation of $3.2M is the 3rd largest of the 9 companies compared; the peer median is $2.23M.
  • Its year-over-year change of -23.9% is the 6th highest of 9, against a peer median of -15.3%.
  • Stock-based compensation amounts to 4.0% of revenue for TELA, versus a peer median of 13.3%.
TELA Competitors Peer median
Stock-Based Compensation for TELA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M -37.3%+4.9%1543.3%
CUECue Biopharma, Inc.LTM Mar 2026$3.45M -44.6%-20.7%10.6%
TELATELA Bio, Inc.LTM Jun 2026$3.2M -23.9%-1.6%4.0%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$2.72M -37.2%-10.8%—
EQEquillium, Inc.LTM Mar 2026$2.63M -22.6%-21.7%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.82M +13.4%—128.8%
MDAISpectral AI, Inc.LTM Mar 2026$1.1M +15.7%-1.2%6.6%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$367K +43.4%-60.2%16.0%
SRTSSensus Healthcare, Inc.LTM Mar 2026$286K -8.0%+16.4%1.3%
Peer median (excluding TELA) $2.23M-15.3%-10.8%13.3%

Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.28M)(44.3M)(46.66M)(37.84M)(38.83M)
Depreciation & Amortization535K1.19M808K1.01M1.01M
Deferred Income Tax14K00(144K)230K
Stock-Based Compensation3.66M3.99M5.03M4.36M3.8M
Change in Working Capital(3.47M)(5.76M)(1.67M)(4.87M)1.5M
Accounts Receivables(1.55M)(2.42M)(3.06M)(762K)(110K)
Inventory(5.19M)(6.07M)(2.72M)(2.97M)(503K)
Accounts Payables1.6M(884K)11K482K141K
Other Working Capital1.69M3.62M4.1M(1.62M)1.97M
Other Non-Cash Items2.1M4.14M1.64M(4.12M)4.08M
Operating Cash Flow(30.43M)(40.75M)(40.86M)(41.6M)(28.22M)
Capital Expenditures(627K)(1.87M)(611K)(989K)(448K)
Acquisitions (Net)00001.29M
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(1M)12K5.44M0
Investing Cash Flow(627K)(1.87M)(599K)4.45M846K
Debt Repayment010M0014.03M
Common Stock Issued585K34.4M46.34M42.92M11.82M
Common Stock Repurchased0000105K
Dividends Paid00000
Other Financing Activities0(3.55M)(74K)138K(205K)
Financing Cash Flow585K40.85M46.27M43.06M25.75M
Effect of Forex Changes11K(144K)164K28K(217K)
Net Change in Cash(30.46M)(1.91M)4.98M5.94M(1.84M)
Free Cash Flow(31.06M)(42.62M)(41.47M)(42.58M)(28.67M)

TELA Bio, Inc.

NASDAQ:TELA

Intrinsic Alpha fair value

Locked

Current Price

$1.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.